What is HC Wainwright's Forecast for TLSI FY2026 Earnings?

Key Points

• HC Wainwright cut its FY2026 EPS forecast for TriSalus Life Sciences to a loss of $0.62 per share from a projected loss of $0.53. The firm kept its Buy rating and $10 price target.
• The company’s latest quarter missed expectations, reporting a $0.15-per-share loss and $12.88 million in revenue, versus estimates of a $0.13 loss and $14.02 million in revenue.
• Analyst opinion is mixed but leans positive: MarketBeat reports a Moderate Buy consensus rating and a $9.20 average price target, while shares opened at $2.52.

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Research analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for shares of TriSalus Life Sciences in a research note issued to investors on Wednesday, November 11th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.62) for the year, down from their prior forecast of ($0.53). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($0.53) per share. HC Wainwright also issued estimates for TriSalus Life Sciences' Q4 2026 earnings at ($0.13) EPS, Q1 2027 earnings at ($0.16) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.10) EPS and FY2027 earnings at ($0.55) EPS.

A number of other research analysts have also recently issued reports on the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TriSalus Life Sciences in a report on Wednesday, November 4th. Zacks Research upgraded shares of TriSalus Life Sciences to a "hold" rating in a research report on Thursday, September 10th. Canaccord Genuity Group decreased their price objective on shares of TriSalus Life Sciences from $7.00 to $4.00 and set a "buy" rating on the stock in a report on Tuesday. Citigroup restated a "buy" rating on shares of TriSalus Life Sciences in a research report on Tuesday. Finally, Stifel Nicolaus set a $12.00 price objective on shares of TriSalus Life Sciences in a research report on Wednesday, September 23rd. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, TriSalus Life Sciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.20.

TriSalus Life Sciences Trading Up 9.6%

Shares of TLSI stock opened at $2.52 on Friday. The stock's fifty day moving average is $4.10 and its 200-day moving average is $4.31. The company has a debt-to-equity ratio of 47.60, a quick ratio of 4.97 and a current ratio of 4.22. TriSalus Life Sciences has a 52 week low of $2.20 and a 52 week high of $7.95.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $12.88 million during the quarter, compared to analysts' expectations of $14.02 million.

Institutional Trading of TriSalus Life Sciences

Hedge funds have recently modified their holdings of the company. First Light Asset Management LLC bought a new position in TriSalus Life Sciences during the 1st quarter worth approximately $20,267,000. BlackRock Inc. bought a new stake in TriSalus Life Sciences in the second quarter valued at approximately $12,099,000. Nantahala Capital Management LLC acquired a new stake in TriSalus Life Sciences in the second quarter worth $4,550,000. White Pine Capital LLC acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $2,143,000. Finally, State Street Corp grew its holdings in shares of TriSalus Life Sciences by 86.3% in the 2nd quarter. State Street Corp now owns 610,963 shares of the company's stock valued at $2,780,000 after buying an additional 282,943 shares during the period. 2.58% of the stock is currently owned by institutional investors and hedge funds.

About TriSalus Life Sciences

TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company's TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.